SCYNEXIS, Inc. Reports Full Year 2014 Financial Results
March 30, 2015 08:30 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., March 30, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the year ended December 31,...
SCYNEXIS, Inc. to Present at Jefferies 2015 Antibiotic Summit
March 12, 2015 08:30 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., March 12, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that members of the SCYNEXIS executive management...
SCYNEXIS, Inc. Appoints Steven C. Gilman, Ph.D., to Board of Directors
February 27, 2015 08:30 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2015 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Steven C. Gilman, Ph.D., to its Board of Directors. Dr. Gilman most...
SCYNEXIS, Inc. to Present at RBC Capital Markets 2015 Healthcare Conference
February 19, 2015 08:30 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' CEO and...
SCYNEXIS Names Marco Taglietti, M.D., Chief Executive Officer
February 06, 2015 07:15 ET
|
SCYNEXIS, Inc.
Yves Ribeill, Ph.D., to Remain President, Serve on Board of Directors
Carole Sable, M.D., Submits Resignation as Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2015 (GLOBE...
SCYNEXIS, Inc. Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections
January 09, 2015 08:30 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food & Drug Administration (FDA)...
SCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
December 03, 2014 08:30 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 3, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Guy Macdonald and Marco Taglietti, M.D., to its Board of Directors. Mr....
SCYNEXIS, Inc. Reports Third Quarter 2014 Financial Results
November 13, 2014 08:30 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the third quarter ended...
SCYNEXIS, Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical for the Development and Commercialization of SCY-635 for Viral Diseases
November 03, 2014 08:35 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 3, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that they have entered into a license agreement granting Waterstone Pharmaceutical (HK)...
SCYNEXIS, Inc. Reports Second Quarter 2014 Financial Results
August 13, 2014 08:00 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the second quarter ended June...